An increase in prostate cancer diagnosis during inflammatory bowel disease: A systematic review and meta-analysis - 20/06/20
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
| páginas | 8 |
| Iconografías | 5 |
| Vídeos | 0 |
| Otros | 0 |
Highlights |
• | IBD was associated with increased PC risks. |
• | Large scale studies are essential to determine association between IBD and PC risk. |
Summary |
Background |
In recent years, some studies showed that inflammatory bowel disease (IBD) might be associated with an increased risk of prostate cancer (PC), whereas some other studies indicated that IBD was not associated with the increased risk of PC. In the present study, we aimed to conduct a systematic review and meta-analysis to evaluate the association of IBD and PC risk.
Methods |
Web of Science and PubMed were systematically searched on for link of PC risk and IBD published from January 1976 to February 2019. The pooled multivariate odd ratio (OR) or relative risk (RR) and 95% confidence intervals (CI) were obtained by the use of STATA 12.0 software.
Results |
The meta-analysis indicated that IBD showed a 78% increase in PC risk (95% CI: 1.32–2.41). Sensitivity analyses showed no changes in the direction of effect after excluding any one study (supplementary figure 1). A significant heterogeneity was detected between different studies (Q test, P<0.001). Moreover, Begg's test, Egger's tests and funnel plots indicated no significant publication bias between included studies [Begg's test (P=0.371); Egger's test (p=0.100)].
Conclusion |
The present meta-analysis demonstrated that IBD was associated with an increased diagnosis of PC. In addition, large scale prospective studies are essential to determine whether IBD increase the PC risk.
El texto completo de este artículo está disponible en PDF.Keywords : Inflammatory bowel disease, Prostate cancer, Meta-analysis
Esquema
Vol 44 - N° 3
P. 302-309 - juin 2020 Regresar al número
Artículo precedente
- Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study
- Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet, Dominique Béchade, Isabelle Trouilloud, Nelson Lourenco, Vincent Hautefeuille, Christophe Locher, Nicolas Williet, Jérôme Desrame, Pascal Artru, Emilie Soularue, Bertrand Le Roy, Julien Taieb
- C1GALT1C1/COSMC is a novel prognostic biomarker for hepatocellular carcinoma
- Bo Shen, Yifan Tong, Zheyong Li, Han Yan, Fang Ye, Yifan Wang, Xiujun XCai
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?